IVVD
Invivyd, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.83
−1.08%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 58.4M | 53.4M | 25.4M | — | — |
| Cost of Revenue | 5.0M | 3.7M | 1.6M | — | — |
| Gross Profit | 53.3M | 49.7M | 23.8M | — | — |
| Operating Expenses | |||||
| R&D Expense | 78.2M | 38.3M | 137.3M | 158.7M | 179.2M |
| SG&A Expense | 87.7M | 66.9M | 63.4M | 49.1M | 47.0M |
| General & Admin Expense | 63.1M | 66.9M | 63.4M | 49.1M | 47.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | 5.0M | 21.8M |
| Total Operating Expenses | 165.9M | 105.2M | 200.6M | 212.8M | 248.0M |
| Cost and Expenses | 170.9M | 109.0M | 202.3M | 212.8M | 248.0M |
| Operating Income (EBIT) | (112.5M) | (55.6M) | (176.9M) | (212.8M) | (248.0M) |
| Non-Operating | |||||
| Interest Income | 4.7M | — | 7.0M | — | 6.7M |
| Interest Expense | — | — | — | — | 43.1M |
| Net Interest Income | 4.7M | — | 7.0M | — | (36.4M) |
| Other Non-Op Income/Expense | 5.2M | 3.1M | 7.0M | 14.1M | 6.7M |
| Non-Operating Income (excl Interest) | (3.9M) | (3.1M) | (7.0M) | (5.0M) | (21.8M) |
| EBT (Pre-Tax Income) | (107.3M) | (52.5M) | (169.9M) | (198.6M) | (241.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (107.3M) | (52.5M) | (169.9M) | (198.6M) | (241.3M) |
| Earnings from Cont. Ops | (107.3M) | (52.5M) | (169.9M) | (198.6M) | (241.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (107.3M) | (52.5M) | (169.9M) | (198.6M) | (241.3M) |
| Per Share | |||||
| Basic EPS | ($0.39) | ($0.30) | ($1.43) | ($1.81) | ($2.17) |
| Diluted EPS | ($0.39) | ($0.30) | ($1.43) | ($1.81) | ($2.17) |
| Revenue Per Share | $0.18 | $0.31 | $0.21 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 320.4M | 172.2M | 118.6M | 109.5M | 108.3M |
| Diluted Shares Outstanding | 320.4M | 172.2M | 118.6M | 109.5M | 108.3M |
| Profitability Metrics | |||||
| EBITDA | (107.3M) | (50.4M) | (166.8M) | (205.8M) | (225.8M) |
| D&A | 1.4M | 2.1M | 3.1M | 2.0M | 462.0K |
| EBIT | (108.7M) | (52.5M) | (169.9M) | (207.8M) | (226.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026